JP2021525705A5 - - Google Patents

Info

Publication number
JP2021525705A5
JP2021525705A5 JP2020565754A JP2020565754A JP2021525705A5 JP 2021525705 A5 JP2021525705 A5 JP 2021525705A5 JP 2020565754 A JP2020565754 A JP 2020565754A JP 2020565754 A JP2020565754 A JP 2020565754A JP 2021525705 A5 JP2021525705 A5 JP 2021525705A5
Authority
JP
Japan
Prior art keywords
alkyl
pde1
pharmaceutical product
substituted
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020565754A
Other languages
English (en)
Japanese (ja)
Other versions
JP7493460B2 (ja
JP2021525705A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/033941 external-priority patent/WO2019227004A1/en
Publication of JP2021525705A publication Critical patent/JP2021525705A/ja
Publication of JP2021525705A5 publication Critical patent/JP2021525705A5/ja
Application granted granted Critical
Publication of JP7493460B2 publication Critical patent/JP7493460B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565754A 2018-05-25 2019-05-24 有機化合物 Active JP7493460B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862676638P 2018-05-25 2018-05-25
US62/676,638 2018-05-25
US201862688641P 2018-06-22 2018-06-22
US62/688,641 2018-06-22
PCT/US2019/033941 WO2019227004A1 (en) 2018-05-25 2019-05-24 Organic compounds

Publications (3)

Publication Number Publication Date
JP2021525705A JP2021525705A (ja) 2021-09-27
JP2021525705A5 true JP2021525705A5 (enExample) 2022-05-27
JP7493460B2 JP7493460B2 (ja) 2024-05-31

Family

ID=68616034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020565754A Active JP7493460B2 (ja) 2018-05-25 2019-05-24 有機化合物

Country Status (11)

Country Link
US (1) US12636287B2 (enExample)
EP (2) EP3802545A4 (enExample)
JP (1) JP7493460B2 (enExample)
KR (1) KR20210013214A (enExample)
CN (1) CN112189013A (enExample)
AU (1) AU2019275453B2 (enExample)
BR (1) BR112020024037A2 (enExample)
CA (1) CA3099283A1 (enExample)
IL (2) IL278935B2 (enExample)
MX (1) MX2020012628A (enExample)
WO (1) WO2019227004A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
MX2024010993A (es) * 2022-03-11 2024-09-17 Intra Cellular Therapies Inc Compuestos organicos.

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690935A (en) 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds
US7783679B2 (en) 2005-01-12 2010-08-24 Computer Associates Think, Inc. Efficient processing of time series data
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
AU2007256633B2 (en) 2006-06-06 2013-09-12 Intra-Cellular Therapies, Inc. Organic compounds
EP2939676A1 (en) 2007-12-06 2015-11-04 Intra-Cellular Therapies, Inc. Organic compounds
ES2588238T3 (es) 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
AU2009322899A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
MX2011005934A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
AU2009322903A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
PE20110922A1 (es) 2008-12-06 2012-01-22 Intra Cellular Therapies Inc DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1)
EA201170769A1 (ru) 2008-12-06 2012-02-28 Интра-Селлулар Терапиз, Инк. Органические соединения
BRPI0922700A2 (pt) 2008-12-06 2015-08-11 Intracellular Therapies Inc Compostos orgânicos
US8993572B2 (en) 2010-04-22 2015-03-31 Intra-Cellular Therapies, Inc. Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
EP2575817A4 (en) 2010-05-31 2014-01-08 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2012177263A1 (en) 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
JP6224597B2 (ja) * 2011-09-27 2017-11-01 バイオメッド バレー ディスカバリーズ，インコーポレイティド グリオーマを処置するための組成物及び方法
WO2013138118A1 (en) 2012-03-14 2013-09-19 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
US9499562B2 (en) 2012-06-18 2016-11-22 Dart Neuroscience (Cayman) Ltd. Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
DK2970279T3 (da) 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
ES2717688T3 (es) * 2013-03-15 2019-06-24 Intra Cellular Therapies Inc Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
WO2014169087A2 (en) 2013-04-10 2014-10-16 The Trustees Of Columbia University In The City Of New York Treatment of proximal spinal muscular atrophy
TW201609713A (zh) 2013-12-19 2016-03-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
TW201611834A (en) 2014-02-07 2016-04-01 Lundbeck & Co As H Hexahydrofuropyrroles as PDE1 inhibitors
EA032579B1 (ru) 2014-04-04 2019-06-28 Х. Лундбекк А/С Галогенированные хиназолин-тгф-амины в качестве ингибиторов pde1
DK3157926T3 (da) 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organiske forbindelser
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
US10849862B2 (en) 2014-12-26 2020-12-01 Theravalues Corporation Formulation of curcumin and anti-PD-1 antibody
TW201643167A (zh) 2015-04-22 2016-12-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並三酮
EP3288980B1 (en) 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
CN110574502B (zh) 2016-09-12 2023-04-18 麦斯卓微电子(南京)有限公司 Mems致动系统和方法
EP4112053B1 (en) 2016-10-11 2024-02-14 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Treatment of synucleinopathies
US10633382B2 (en) 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
MA46716A (fr) * 2016-11-03 2019-09-11 Juno Therapeutics Inc Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
CA3047579A1 (en) 2016-12-22 2018-06-28 Abbvie Inc. Compositions and methods of enhancing or augmenting type i ifn production
AU2018325445A1 (en) 2017-08-31 2020-03-19 Abbvie Inc. Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitors and uses thereof
EP3856191A4 (en) 2018-09-25 2022-06-22 Intra-Cellular Therapies, Inc. NOVEL USES
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US12599603B2 (en) 2019-09-03 2026-04-14 Intra-Cellular Therapies, Inc. Methods of treatment
MX2024010993A (es) 2022-03-11 2024-09-17 Intra Cellular Therapies Inc Compuestos organicos.

Similar Documents

Publication Publication Date Title
JP2022546711A5 (enExample)
JP2022185107A5 (enExample)
MX2025013001A (es) Inhibidores espiro-heterocíclicos de las proteínas mutantes kras g12c y usos de los mismos.
RU2429226C9 (ru) Ингибиторы пролилгидроксилазы и способы их применения
EA200601252A1 (ru) Новый класс веществ, вызывающих дифференцировку клеток и являющихся ингибиторами гистондеацетилазы, и способы их применения
ATE374763T1 (de) Bisarylsulfonamid-derivate und ihre verwendung für krebs therapie
JP2017528498A5 (enExample)
KR930702292A (ko) 종양 치료 활성을 증대시키기 위한 퀴나졸린 유도체
RU98117314A (ru) Тропановые производные, их получение и применение
RU2005137403A (ru) Новые замещенные 3-сера-индолы
RU2005104819A (ru) Ингибиторы фосфодиэстеразы 4, включающие n-замещенные аналоги анилина и дифениламина
JP2025163128A5 (enExample)
JP2023510746A5 (enExample)
JP2023509359A5 (enExample)
JP2025509446A5 (enExample)
JP2020527173A5 (enExample)
KR20050051658A (ko) ＩｇＥ를 조절하고 세포 증식을 억제하기 위한 페닐-인돌화합물
JP2008517923A5 (enExample)
ATE368643T1 (de) Faktor xa benzamidin inhibitoren
BR112012017705B1 (pt) Derivados de sulfonamidas de 3,4-diarilpirazóis como inibidores da proteína cinase
RU2006128788A (ru) Производные фенил[4-(3-фенил-1н-пиразол-4-ил)пиримидин-2-ил] амина в качестве igf-1r ингибиторов
CA2526989A1 (en) Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors
JP2006522824A5 (enExample)
RU2010107603A (ru) Производные n-(2-тиазолил)амида для лечения ожирения, диабетов и сердечно-сосудистых заболеваний
RU98119076A (ru) Производные 2-(3h)-оксазолона и их применение в качестве ингибиторов сох-2